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Abstract
Objectives: The purpose of current neuro-ophthalmologic research is to evaluate visual
dysfunction and its correlation with structural changes in the retina of patients with
Parkinson’s disease and to examine whether there is an association between retinal
thinning and disease progression.
Methods: Patients with Parkinson’s disease and controls were included in a series of
observational  cross-sectional  studies  and  underwent  visual  function  evaluation.
Structural measurements of different layers of the retina were obtained using spectral
domain optical coherence tomography (SD-OCT). Disease severity was assessed using
the Schwab–England Activities of Daily Living scale, the Unified Parkinson Disease Rating
Scale, and the Hoehn and Yahr (HY) scale. Comparison of obtained data and correla‐
tion  analysis  between  functional  and  structural  results  and  disease  severity  was
performed. The diagnostic ability of SD-OCT for the detection of Parkinson disease was
also tested by the development of two linear discriminant functions (LDFs).
Results: Patients with Parkinson’s disease had altered visual function and presented
retinal thinning in different sectors. Disease progression correlated with retinal
parameters and measurements of retinal thickness was differentiated between healthy
subjects and those with advanced Parkinson’s disease.
Keywords: Parkinson’s disease, optical coherence tomography, retinal nerve fiber lay‐
er, retinal ganglion cells, macular thickness
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1. Introduction
Parkinson’s disease (PD) is well known for its motor symptoms, such as bradykinesia, rigidity,
resting tremor, and postural instability. However, the loss of dopaminergic neurons also leads
to non-motor alterations, such as depression, dementia, and autonomic dysfunction [1].
Vision is one of the non-motor systems altered in PD. Patients suffering from Parkinson´s are
reported to have decreased visual acuity (VA), contrast sensitivity, and color vision [2–8].
Recent research demonstrated that retinal thinning in PD patients and axonal damage can be
detected and quantified using ocular imaging technologies, such as optical coherence
tomography (OCT). The retina is part of the central nervous system and is easily accessible to
clinical examination. The retinal nerve fiber layer (RNFL) comprises mainly non-myelinated
axons of retinal ganglion cells (RGCs), so RNFL thickness measurements provide a relative‐
ly direct assessment of the axons and axonal damage.
OCT provides cross-sectional images of the retina and optic disc based on interference patterns
produced by low coherence light reflected from retinal tissues. This technology includes the
development of parameters to provide quantitative, objective, and reproducible measure‐
ments of the different retinal layers. Recent research on segmentation and analysis of differ‐
ent retinal layers has shown that measures of specific layers, such as the RGC layer provide
more accurate information about axonal loss in neurodegenerative diseases [9].
Dopamine in the human retina is released by a set of amacrine cells. These dopaminergic cells
are located in the proximal inner nuclear layer of the retina and send long processes to other
retinal layers. Dopamine in the mammalian retina modulates color vision and contrast
sensitivity through dopaminergic receptors (D1 and D2), which are differentially located in
the retinal layers. A complete lack of D1 and D2 receptor activation leads to signal disper‐
sion and alterations in color vision and contrast sensitivity.
The diagnosis of idiopathic PD is based on medical history and neurologic examination, and
it sometimes takes several years to obtain a definitive diagnosis. Thus, new technologies and
accurate tests are needed to improve and accelerate the diagnostic procedure in early stages
of PD.
Recent research using OCT technology has demonstrated that parameters provided by OCT
are accurate to detect various inner retinal or optic nerve pathologies, such as multiple
sclerosis, PD, or Alzheimer disease [10–15]. At present, no clear guidelines are available on
whether one, several, or all of the retinal parameters provided by OCT can be used in the
diagnosis of PD.
Current research in the field of neuro-ophthalmology focuses on the evaluation of visual
dysfunction in PD and its correlation with retinal alterations in these patients. Recent studies
in PD have evaluated the association between macular, ganglion cell layer, and RNFL defects
and PD severity, as well as the possible diagnostic ability of OCT technology [9, 15, 16].
The main objective of this study was to provide a better understanding of the role of retinal
layers in PD and a diagnostic tool for the early detection of this neurodegenerative pathology.
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2. Neuro-ophthalmologic evaluation of PD patients
2.1. Visual dysfunction in PD
Vision comprises many simultaneous functions that are important for daily life activities, such
as mobility, reading, driving, and facial recognition [17–20]. Thus, it is important to assess the
functional capability of the visual pathways by measuring VA, color vision, visual fixation,
objects visual tracking, and contrast sensitivity and to evaluate the impact of vision loss on a
person’s ability to perform everyday visual tasks.
PD patients are reported to have decreased contrast sensitivity and color vision [2–8]. Previous
studies have indicated that PD patients lose foveal contrast sensitivity to patterns to which
normal observers are most sensitive (that is, requiring the least contrast for detection of letters,
shapes, and figures) [3, 4]. In the retina, ganglion cells adapt to visual contrast and pool the
visual information of their receptive fields through a network of parallel bipolar cells with
smaller receptive fields [21]. Additionally, contrast sensitivity and color vision are modulat‐
ed through dopaminergic receptors, which are located in the inner retinal layers. A complete
lack of activation of these receptors leads to signal dispersion and alterations in color vision
and contrast sensitivity [22].
In our hospital, we evaluated a cohort of 37 patients with PD and analyzed possible altera‐
tions in their visual function. We assessed VA, contrast sensitivity vision (CSV), and color
vision in these patients and compared the results with healthy controls.
The diagnosis of PD was based on standard clinical and neuroimaging criteria [23]. Patients
with significant refractive errors (>5 diopters of spherical equivalent refraction or 3 diopters
of astigmatism), intraocular pressure ≥21 mm Hg, media opacifications, concomitant ocular
diseases including history of glaucoma or retinal pathology, and systemic conditions that
could affect the visual system were excluded from the study. The healthy controls had no
history and no evidence of ocular or neurologic disease of any nature, and their best-correct‐
ed visual acuity (BCVA) was >20/30 based on the Snellen scale, to ensure all of them could
complete the visual function evaluation tests. All subjects underwent a complete neuro-
ophthalmic evaluation that included pupillary, anterior segment, and funduscopic examina‐
tion. All procedures adhered to the tenets of the Declaration of Helsinki, and all participants
provided informed consent to participate in the study.
Visual function was assessed by evaluating different functional parameters: BCVA using an
ETDRS chart; CSV using the CVS-1000E test and Pelli–Robson chart; and color vision using
the Farnsworth D15 and L´Anthony D15 tests.
VA is a measure of the spatial resolution of the visual processing system and is dependent on
optical and neural factors, that is, the sharpness of the retinal focus within the eye, the health
and functioning of the retina, and the sensitivity of the interpretative faculty of the brain. Thus,
the VA in a patient with PD and a healthy eye will depend solely on their neurologic condi‐
tion. VA can be evaluated using different optotypes (with letters or numbers). For clinical
research, the ETDRS chart is considered the gold standard and consists of a set of 10 letters
from the Roman alphabet, each of them equally visible (Figure 1).
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Figure 1. ETDRS charts for evaluation of high and low contrast visual acuity. (A): 100% contrast ETDRS chart. (B:)
2.50% contrast ETDRS chart.
The letters are arranged in 14 rows, with 5 letters each, and decrease in size progressively.
Results can be expressed as 6/6, 10/10, decimal value or logarithmic scale (LogMar). In the
expression 6/6, at 6 m, a human eye with a VA of 6/6 is able to separate contours that are
approximately 1.75 mm apart; 6/12 means that a person with 6/6 vision would discern the same
optotype from 12 m away (i.e., at twice the distance). The equivalent to 6/6 in decimal digits
would be 1.0 and 0.0 in logarithmic scale (LogMar). In our patients, LogMAR VA was evaluated
at three different contrast levels: 100, 2.50, and 1.25% (using Low-Contrast Sloan Letter Charts),
the percentage indicating the level of contrast, that is, 100% representing black letters over
white background and 1.25% light grey letters over white background (Figure 1).
CSV provides more complete information about visual function than VA tests. CSV was
evaluated in our patients using the Pelli–Robson chart and the CSV-1000E test. The Pelli–
Robson is a commonly used test for the evaluation of contrast sensitivity, assessing CSV at one
spatial frequency (1 cycle/degree [cpd]). This chart comprises horizontal lines of capital letters
organized into groups of three (triplets) with two triplets per line. Within each triplet, all letters
have the same contrast. The contrast decreases from one triplet to the next, even within each
line. All patients were evaluated at a distance of 1 m from the chart and under controlled fotopic
conditions (85 cd/m2). The score corresponding to the last triplet of letters seen by the patient
was recorded. The CSV-1000E instrument is used worldwide for standardized CSV and glare
testing and evaluates CSV at 4 different spatial frequencies (3, 6, 12, and 18 cpd). The chart
comprises four rows with 17 circular patches each. The patches present a grating that decreases
in contrast moving from left to right across the row (Figure 2). Each contrast value for each
spatial frequency was transformed into a logarithmic scale according to standardized values.
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Figure 2. Contrast sensitivity vision tests. (A) Pelli–Robson chart explores contrast sensitivity in one spatial frequency
(1 cycle per degree). (B) CSV 1000E test evaluates contrast sensitivity at four different spatial frequencies (3, 6, 12, and
18 cycles per degree).
Color vision was evaluated using the Color Vision Recorder (CVR) program. CVR software is
designed for the Windows operating system and analyzes chromatic discrimination by
classification of colors (color arrangement using colored caps). CVR includes several classic
color tests. All patients in the study were evaluated using the Farnsworth D15 and L´Anthony
D15 tests. These tests are often used to differentiate between subjects with severe loss of color
vision and those with milder color defects or normal color vision. Different output parame‐
ters, such as the age-corrected color confusion index (AC CCI, which represents the ratio
between the radius or distance between caps), the Confusion angle (Conf angle, which
represents the axis of color deficiency), and the Scatter index (S-index, which represents the
parallelism of confusion vectors to the personal confusion angle) were recorded [24, 25]. All
these parameters evaluate the severity of dyschromatopsia. For example, an AC CCI score
higher than 1, indicates altered color vision perception; the higher the score in the AC CCI and
the S-index, the worse the color deficiency.
We found that our patients with PD had a lower BCVA at all three contrast levels of the
ETDRS chart compared to the controls (0.18 ± 0.26 in patients vs. −0.065 ± 0.9 in controls at
100%, p = 0.001; 0.59 ± 0.21 vs. 0.44 ± 0.13 at 2.50%, p = 0.01; and 0.61 ± 0.23 vs. 0.58 ± 0.16 at
1.25%, p = 0.009). The Pelli– Robson results revealed a significant reduction in CSV in PD
patients (p = 0.02). CSV was also affected in patients at all four spatial frequencies of the CSV
1000E chart (3, 6, 12, and 18 cpd; p = 0.001, <0.001, <0.001, and 0.004 respectively). Color vi‐
sion was also affected in PD: In our patients, only the L´Anthony test results were signifi‐
cantly altered. L´Anthony test is less saturated than the Farnsworth color test; thus, it is
designed to detect very subtle color deficiencies. Our patients performed worse than con‐
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trols in both tests (higher C-index and S-index, reaching ranges similar to protanomalies),
although only the differences in L´Anthony S-index were statistically significant, indicating
that our patients had a (subtle) protanomaly (Table 1).
Healthy controls Parkinson’s disease P
Mean SD Mean SD
VA ETDRS 100 −0.06 0.096 0.18 0.26 0.001
VA ETDRS 2.5 0.44 0.13 0.59 0.22 0.010
VA ETDRS 1.25 0.58 0.16 0.62 0.23 0.009
Pelli–Robson 1.89 0.11 1.71 0.17 0.002
CSV 1000 3 cpd 1.72 0.16 1.49 0.35 0.001
CSV 1000 6 cpd 1.94 0.13 1.62 0.34 0.000
CSV 1000 12 cpd 1.62 0.17 1.26 0.41 0.000
CSV 1000 18 cpd 1.11 0.22 0.73 0.34 0.004
Farnsworth AC CCI 1.11 0.22 0.73 0.34 0.851
Farnsworth Conf Angle 63.90 11.15 65.84 7.49 0.392
Farnsworth S-index 1.56 0.22 1.64 0.39 0.278
Farnsworth time 78.67 28.96 82.91 33.10 0.616
L´Anthony AC CCI 1.05 0.19 1.02 0.18 0.489
L´ Anthony Conf Angle 62.31 14.74 71.91 9.25 0.002
L´ Anthony S-index 1.69 0.43 1.95 0.48 0.020
L´ Anthony time 77.14 25.99 84.09 39.31 0.431
Results in bold letters indicate statistical significance (p < 0.05).
AC CCI, age-corrected color confusion index; Conf Angle, confusion angle; cpd, cycles per degree; ETDRS, early
treatment diabetic retinopathy study; PD, Parkinson disease; S-index, scatter index; VA, visual acuity.
Table 1. Mean and standard deviation (SD) of visual functional parameters in healthy controls and subjects with
Parkinson’s disease. Results in bold letters indicate statistical significance (p < 0.05).
Ganglion cells in the retina show adaptation to visual contrast. The parvo- and magnocellu‐
lar ganglion cells are located in the RGC layer and take two different pathways for the iden‐
tification of color and contrast at different frequencies [26]. RGC loss was recently identified
as the cause of visual impairment in patients suffering from another neurodegenerative
process (multiple sclerosis) [27]. Thus, a similar process could be the cause of the contrast
and color deficiencies in PD.
The results found in this study highlight the importance of visual function tests in the
evaluation of PD patients and may have important implications for clinical diagnosis of
functional deficits in these patients.
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2.2. Retinal changes in PD
Parkinson´s disease has been associated with alterations in foveal vision. This visual altera‐
tion seems to be caused by a dysfunction of the intraretinal dopaminergic circuitry and final
retinal output to the brain [2].
Thanks to the new digital imaging technologies applied in the field of ophthalmology, an
objective assessment of the retinal layers is now possible. OCT provides a rapid, objective, non-
invasive, and reproducible method for the assessment of eye structures thicknesses and
volumes.
OCT is an established medical imaging technique that uses light to capture micrometer-
resolution, three-dimensional images from within optical scattering media. OCT is based on
low-coherence interferometry, usually employing near-infrared light. The use of relatively
long wavelength light allows it to penetrate into the scattering medium. The interference of
light (caused by the different tissues) occurs at a distance of micrometers. Light with broad
bandwidths can be generated using superluminescent diodes or lasers with extremely short
pulses.
The OCT device combines the reflected light from two arms (one arm containing the object of
study, and a second arm containing usually a mirror) to rise an interference pattern. A
reflectivity profile of the sample is obtained by scanning the mirror in the reference arm [28].
Parts of the sample that reflect a lot of light will create greater interference than areas that do
not. These higher interference areas will be seen as bright patterns and will correlate with
fibrosis or dense retinal layers, whereas low interference areas will be seen as dark patterns
and will correlate with fluid. Any light that is outside the short coherence length will not
interfere.
There are many studies on neurodegenerative diseases using OCT to detect changes in the
RNFL thickness and macular morphology. Regarding PD and the alteration of macular
thickness, recent studies have shown a significant thinning in the retinal inner layers of the
macular area in patients with PD. Alterations of the retinal layers in PD patients were first
demonstrated in 2004 [29]. Since then, various studies have reported different results [29–33].
For the past 5 years, the neuro-ophthalmology research team of Miguel Servet University
Hospital has studied retinal structural alterations in PD patients using different OCT devi‐
ces. Various software applications were used in the evaluation of these patients.
A first cohort of 153 subjects with PD underwent OCT examinations using the Cirrus high-
definition (HD) OCT device and the Spectralis OCT device. Two different applications were
used for Spectralis OCT, for the analysis of the optic nerve: the Glaucoma application (which
scans the optic nerve head starting and finishing in the temporal quadrant), and the Axonal
Analytics application for neurodegenerative diseases (which scans the optic nerve from and to
the temporal quadrant) (Figure 3.).
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Figure 3 Evaluation of the retinal nerve fiber layer using Axonal Analytics application for Spectralis OCT. (A) Arrow
marks the direction of the scan in the optic nerve head. (B) Cross-sectional image of the peripapillary retinal thickness.
The retinal layers can be observed in different colors, depending on their interference pattern. (C) OCT report with
measurements of the retinal nerve fiber layer in μm.
The difference between both applications resides in the sector with the most accurate meas‐
urements: With Glaucoma application, the most accurate sector is nasal, and with Axonal
Analytics application is the temporal sector, which is precisely the sector with earlier affecta‐
tion in neurodegenerative diseases. Macular and peripapillary RNFL thicknesses were
evaluated and compared with thicknesses of a group of 242 healthy individuals [9].
The Spectralis OCT measurements revealed significant differences in most of the RNFL sectors
using the traditional Glaucoma application, and in the mean thickness, the inferior quadrant,
the inferonasal, and the inferotemporal RNFL sectors using the Axonal Analytics application.
The Cirrus OCT measurements revealed significant RNFL differences in mean thickness, and
thickness of superior, inferior, and temporal quadrants. Macular thickness was also reduced
in patients with PD for all measurements of the inner and outer macular sectors using the
Spectralis OCT device; and for the central sector (fovea thickness) and the nasal outer and
inferior outer sectors with the Cirrus OCT. Results from this study were published in the British
journal of Ophthalmology in 2014.
A different cohort of patients underwent retinal evaluation with a new prototype technique
for retinal segmentation using the Spectralis OCT [16]. This new software is designed to
identify each retinal layer and to measure its thickness. Segmentation of the retinal layers in
single horizontal foveal scans was performed automatically by the segmentation application
into 10 different layers [16] (Figure 4.).
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Figure 4 Macular cross-sectional image of a patient with Parkinson’s disease, as provided by the segmentation applica‐
tion of Spectralis OCT. The different retinal layers can be observed marked in different colored lines.
All measurements of the macular and peripapillary thickness of the 10 layers were regis‐
tered in a database for all eyes, and mean thickness of each retinal layer was calculated. A total
of 129 eyes from 129 PD patients and 129 eyes of 129 healthy subjects were included in the
study.
The segmentation application revealed a significant reduction of the RNFL, ganglion cell layer,
the inner plexiform, and outer plexiform layer thickness in PD patients compared with
controls. Surprisingly, the inner nuclear layer was significantly thicker in PD patients
compared with healthy subjects (Table 2). These results were published in 2013 in the American
Journal of Ophthalmology.
LAYER Parkinson’s disease (n = 129) Healthy subjects (n = 129) P*
Inner glial limiting membrane 5.69 ± 2.01 5.68 ± 1.72 0.563
Retinal nerve fiber layer 6.06 ± 1.90 6.26 ± 1.80 0.036
Ganglion cell layer 6.30 ± 1.89 6.49 ± 1.86 0.011
Inner plexiform layer 6.64 ± 1.95 6.77 ± 1.92 0.016
Inner nuclear layer 7.39 ± 1.94 7.14 ± 1.90 0.033
Outer plexiform layer 7.17 ± 1.93 7.31 ± 1.91 0.028
Outer nuclear layer 7.89 ± 1.91 7.95 ± 1.92 0.085
Outer glial limiting membrane 8.20 ± 1.90 8.25 ± 1.96 0.220
Photoreceptors 8.26 ± 1.98 8.29 ± 1.95 0.139
Retinal pigment epithelium 8.58 ± 1.88 8.63 ± 1.89 0.397
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Table 2. Mean and standard deviation of retinal thickness in the 10 different retinal layers automatically provided by
the segmentation application of the Spectralis optical coherence tomography and comparison between patients with
Parkinson’s disease and healthy subjects.
The correlation between retinal changes and visual dysfunction in patients suffering from PD
was also investigated. A small cohort of 37 patients with PD (37 eyes) underwent visual
function tests (see previous section Visual dysfunction in Parkinson´s disease) and structural
analysis of macular thickness, ganglion cell layer (GCL) and RNFL thickness, and linear
correlations between functional and structural results were calculated using Pearson’s
correlation coefficient.
Results demonstrated that CSV was the functional parameter most frequently associated with
structural measurements in PD. The Pelli– Robson CSV results correlated with GCL thick‐
ness in all sectors, although the association was not strong (r < 0.5, p < 0.05). The Pelli– Robson
measurements also correlated with the thicknesses in different sectors of the peripapillary
RNFL (average, superior, and inferior sectors). The CSV-1000E measurements at different
spatial frequencies correlated significantly with most GCL measurements: The spatial
frequency of 6 cpd correlated with the superonasal thickness (r = 0.40, p = 0.013), with the
superotemporal thickness (r = 0.44, p = 0.006), with the average GCL + IPL thickness (r = 0.40,
p = 0.012), and with the minimum GCL + IPL (r = 0.40, p = 0.011). The spatial frequency of 18
cpd correlated with the superotemporal thickness (r = 0.41, p = 0.01) and the minimum GCL +
IPL thickness (r = 0.43, p = 0.006), showing here the strongest correlations with GCL thick‐
ness. Spatial frequencies of 6 and 18 cpd were strongly correlated with average macular
thickness (r = 0.79, p = 0.012; r = 0.77, p = 0.016, respectively) and macular volume (r = 0.78, p
= 0.013; r = 0.78, p = 0.014, respectively). Color vision was also associated with the structural
parameters, but only those measurements (the C-index and CCI) assessed by the L´Anthony
test were significantly correlated with all outer macular parameters and most of the GCL
measurements. A significant association between color vision and the RNFL parameters was
only found in isolated sectors.
The VA ETDRS results (high and low contrast) correlated strongly with average macular
thickness and macular volume (Table 3). This was particularly interesting, since this is the first
time such a strong correlation between macular thickness, macular volume, and functional
parameters (VA and CSV) is reported (r > 0.70).
Macular thickness
(correlation coefficient)
P value Macular volume
(correlation coefficient)
P value
VA ETDRS 100 −0.765 0.006 −0.761 0.007
VA ETDRS 1.25 −0.718 0.013 −0.715 0.013
VA ETDRS 2.50 −0.738 0.010 −0.729 0.011
Correlation data in bold type are statistically significant (p value < 0.05).
ETDRS, early treatment diabetic retinopathy study; VA, visual acuity.
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Table 3. Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and
macular structural measurements (thickness and volume) in patients with Parkinson disease. Results in bold letters
indicate statistical significance (p < 0.05).
The study on the association between structural and functional parameters is currently pending
acceptance for its publication in a peer- reviewed journal.
2.3. Correlation between structural changes and disease severity
The stage and severity of PD were determined in all our patients based on three different rating
scales: the Hoehn and Yahr (HY), the Schwab–England activities of daily living (ADL), and
the Unified Parkinson’s disease rating score (UPDRS). Patients were tested by a trained
neurologist who was blind to the ophthalmology results. Disease duration was also record‐
ed, setting the appearance of the first symptoms as the onset time of the disease.
A correlation analysis between disease severity and structural changes as measured by OCT
was performed in the first cohort of patients (153 patients with PD). Correlations between
structural data (measured with Cirrus OCT and Spectralis OCT) and the different rating scales
were examined by Pearson’s test. The results of this study were published in the British Journal
of Ophthalmology, in 2014 [9].
The correlation analysis revealed an inverse correlation between most macular thickness
measurements assessed by Spectralis OCT and the scores on the HY scale. This means that
increased neurological effects and severity of PD progression are linked to thinning of macular
tissue. There was a significant correlation between the Schwab–England ADL scores and the
outer temporal macular thickness measured with the Cirrus OCT device (r = 0.284, p = 0.010);
and between the Schwab–England ADL scores and the inner inferior macular thickness
measured with the Spectralis OCT device (r = 0.217, p = 0.039). The UPDRS scores were
significantly correlated with the inner inferior macular thickness and measured using the
Cirrus OCT device (r = −0.331, p = 0.032). Disease duration was correlated with RNFL thickness
measured by the Spectralis OCT device (nasal quadrant using glaucoma application, p = 0.036;
nasal quadrant and mean thickness using axonal application, p = 0.016 and p = 0.038, respec‐
tively). No correlation between disease duration and Cirrus OCT values was found.
In the second cohort (129 patients and 129 healthy controls), PD patients were divided into
two groups depending on disease duration: <10 years (67% of the patients) or at least 10
years (33%). The thickness of the different retinal layers was compared between both pa‐
tient’s groups using Student’s t-test. Linear agreement between the mean thickness of each
retinal layer and three neurologic parameters (duration of disease, HY, and UPDRS scores)
was obtained using the Pearson correlation coefficient. A logistical regression analysis was
performed to identify which retinal layer thicknesses predicted axonal damage in PD patients.
When analyzing the results, the inner retinal layer thicknesses (RNFL, ganglion cell, and inner
plexiform layers) were more affected in PD patients with disease duration of at least 10
years (Table 4). GCL thickness correlated inversely with PD duration (r = −0.221, p = 0.046)
and the HY scale (r = −0.311, p = 0.041), but not the UPDRS scale.
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Layer Parkinson’s disease
patients with disease
duration < 10 years (n:86)
Parkinson’s disease
patients with disease
duration ≥ 10 years (n:43)
P*
Inner glial limiting membrane 5.70 ± 1.95 5.68 ± 1.96 0.211
Retinal nerve fiber layer 6.06 ± 1.87 5.89 ± 1.91 0.028
Ganglion cell layer 6.40 ± 1.92 5.96 ± 1.85 0.031
Inner plexiform layer 6.47 ± 1.91 6.11 ± 1.89 0.009
Inner nuclear layer 7.37 ± 1.91 7.41 ± 1.75 0.111
Outer plexiform layer 7.19 ± 1.91 7.08 ± 1.99 0.136
Outer nuclear layer 7.89 ± 1.98 7.82 ± 1.93 0.356
Outer glial limiting membrane 8.21 ± 1.79 8.20 ± 1.95 0.457
Photoreceptors 8.27 ± 1.90 8.24 ± 1.89 0.665
Retinal pigment epithelium 8.60 ± 1.85 8.57 ± 1.93 0.763
Table 4. Mean and standard deviation of thicknesses in the 10 retinal layers automatically provided by the new
segmentation application of the Spectralis optical coherence tomography and comparison between Parkinson disease
patients with disease duration of <10 years or at least 10 years.
The regression analysis showed that only the GCL thickness could predict axonal atrophy in
PD. Based on the OCT measurements, PD patients with thinner GCL thickness showed a
greater decrease in average RNFL thickness. However, thickness of the other retinal layers was
not predictive of axonal damage. These results were published in the American Journal of
Ophthalmology, in 2013 [16].
Our data clearly revealed that disease duration has an impact on the thickness of the RNFL,
the GCL, and the inner plexiform layer. The negative correlation between macular thickness,
the thickness of the RNFL, and the Hoehn and Yahr score indicates that patients with greater
axonal damage tend to have more severe PD symptoms. Our results also indicated that GCL
thickness could predict axonal damage in PD patients. GCL atrophy is thought to be a
component of RNFL loss, which is suggested to produce consecutive degeneration of the RGC
layer and its axons as disease progresses [34, 35].
2.4. The role of OCT in the diagnosis of Parkinson´s disease
Because of the difficulty in diagnosing PD, medical organizations have created diagnostic
criteria to standardize and simplify the diagnostic process. Diffusion magnetic resonance
imaging is a specific technique that may help discriminate between typical and atypical
parkinsonism, but its exact diagnostic value is still under investigation.
A definitive diagnosis for PD may take years. Thus, new technologies and accurate tests are
needed to improve and accelerate the diagnostic procedure in early stages of the disease.
Currently, there are no clear guidelines available on which retinal or RNFL parameters
provided by OCT can be used in the diagnosis of PD. Previous research demonstrated that
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overall RNFL mean thickness provided by OCT is a good parameter to detect various inner
retinal or optic nerve pathologies, such as glaucoma [11], and neurodegenerative disease [10].
Optimal neurodegenerative disease detection, however, is liable to depend on a combina‐
tion of several parameters. In 2013, our research team published a study in the journal Retina
that evaluated whether a selective combination of RNFL and retinal OCT parameters could
further optimize PD diagnosis. The purpose of this study was to evaluate the diagnostic ability
of a linear discriminant function (LDF) for PD, based exclusively on ophthalmologic parame‐
ters.
Two independent samples of 100 consecutive healthy subjects and 60 idiopathic patients with
PD were recruited from two clinics in the hospital area. The diagnosis of PD was based on the
United Kingdom’s BrainBank criteria and the United States National Institute of Neurologi‐
cal Disorders and Stroke criteria [36].
All subjects underwent OCT evaluation to obtain measurements of the peripapillary RNFL
and retinal thickness using the Spectralis OCT device. Regression analysis was used, when the
dependent variable (to have PD) was dichotomous (yes/no) and the independent variables
(all OCT measurements) were of any kind. For logistic regression analysis, the probability that
a subject has PD was set as the predicted-dependent variable. The relative importance of each
independent variable was evaluated using the forward Wald method, which tests the unique
contribution of each predictor in the context of the other predictors. The LDF was calculated
by taking the weighted sum of the predictor variables. The significant OCT parameters were
combined to generate a new variable (LDF) in such a way that the measurable differences
between healthy eyes and eyes with PD were maximized. One hundred and eleven eyes
from 60 patients with PD were evaluated. All RNFL scans and retinal measurements provid‐
ed by the Spectralis OCT were analyzed to calculate three LDFs: the Retinal LDF using the 9
retinal measurements (macular area), the RNFL LDF with 768 RNFL measurements, and the
definitive LDF (which combined all OCT measurements). The statistical analysis showed that
the Retinal LDF was the best formula. Retinal LDF was defined as follows: 31.173 + temporal
outer thickness × 0.026 − superior outer thickness × 0.267 + nasal outer thickness × 0.159 −
inferior outer thickness × 0.197 − superior inner thickness × 0.060 + foveal thickness × 0.049 [36].
For the Retinal LDF, the area under the ROC curves was 0.900 (Table 5).
OCT parameters AUC 95% CI AUC P-value Cut-off point Sens (%) Spec (%)
Retinal LDF 0.900 0.862–0.933 <0.001 >−58.4 89.5 80.5
Foveal thickness 0.467 0.409–0.525 0.345 >305 22.4 96.5
Temporal inner thickness 0.737 0.684–0.787 <0.001 ≤327 66.3 75.5
Temporal outer thickness 0.680 0.624–0.733 <0.001 ≤277 47.2 83.5
RNFL LDF 0.824 0.777–0.865 <0.001 >−0.84 85.6 63.5
RNFL average thickness 0.535 0.478–0.592 0.185 <86 17.1 96.5
RNFL temporal thickness 0.574 0.517–0.630 0.083 >77 32.4 86.5
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OCT parameters AUC 95% CI AUC P-value Cut-off point Sens (%) Spec (%)
RNFL PMB sector 0.567 0.510–0.623 0.037 >52 65.7 50.0
RNFL N/T index 0.586 0.529–0.641 0.016 ≤1.16 65.7 52.5
AUC, area under the receiver operating characteristic curve; CI, confidence interval; LDF, linear discriminant function;
OCT, optical coherence tomography; RNFL, retinal nerve fiber layer; Sens, Sensitivity; Spec, Specificity.
Table 5. In the validating set, areas under the receiver operating characteristic curves, best sensitivity-specificity
balance, and likelihood ratios of retinal nerve fiber layer parameters of the Nsite Axonal Analytics software of
Spectralis optical coherence tomography (OCT) to discriminate between normal subjects and patients with Parkinson’s
disease.
The largest areas under the ROC curves were those for the Temporal Inner and Outer retinal
thickness [36].
3. Discussion
Parkinson’s disease patients present decreased high and low contrast VA and CSV, and mild
anomalies in color perception. Visual dysfunction in PD is frequently underdiagnosed, since
tests designed to detect abnormalities in visual function are not routinely performed in eye
examination, and symptoms often go unnoticed by patients.
Neurodegeneration caused by PD can be detected using OCT. Our studies, along with previous
research, revealed a reduction in retinal thickness (specifically in the macular area), RNFL and
RGC thicknesses in patients suffering from PD. The loss of RGCs has been linked to visual
dysfunction and may also be responsible for visual function anomalies in PD patients.
The loss of RGCs leads to a corresponding decrease in retinal and RNFL thicknesses that can
be detected using OCT [37, 38]. In PD patients, this loss could be due to primary neurodegen‐
eration of the RGCs and their axons or to retrograde degeneration of the RGC layer plus its
axons produced by PD lesions of the posterior visual pathways [39]. Retrograde RGC
degeneration produced by retrogeniculate lesions was previously reported in patients with
homonymous hemianopia [40], which suggests that OCT measurements reveal combined
anterior and posterior visual pathway disease [40, 41].
Our results revealed macular thinning of all areas in patients with PD compared with controls,
an inverse correlation with HY and UPDRS severity, and a positive correlation with the
Schwab–England ADL scale. Therefore, increased neurologic alterations and severity of PD
progression are linked to thinning of macular tissue. The degree of correlation, although
significant, was low moderate. These results, however, are consistent with findings in other
neurodegenerative diseases [42].
Our segmentation analysis revealed that the GCL thickness was inversely correlated with
disease duration and PD severity and was predictive of axonal damage in PD patients. We
believe that further research with segmentation application is needed to establish the extent
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to which each retinal layer can predict PD in particular circumstances (e.g., recognizing PD
when in an early stage), or to evaluate the effectiveness of different treatments.
The retinal measurements provided by Fourier domain OCT technology are tools that can be
used in combination with other parameters and clinical explorations. LDF calculated upon
OCT parameters may be more sensitive and specific than the methods currently used for
diagnosis. Our Retinal LDF yielded higher sensitivity (at a high specificity) than any single
parameter determined using OCT. The high sensibility and specificity demonstrated by OCT
may be better than some of the accepted neuroimaging criteria in the current PD diagnosis
procedure.
The LDFs presented in our study, however, demonstrate better accuracy for PD diagnosis in
patients with advanced disease. Clinical application of our findings may help diagnosis in
patients who suffer from movement alterations, and PD is suspected. Our results indicate that
retinal thinning may be useful for detecting patients with PD. However, larger studies using
OCT technology are needed to evaluate the sensitivity, specificity, and the ability of retinal
thickness measurements to detect PD. Longitudinal prospective studies should be carried out
in the future, to assess disease progression and treatment effectiveness.
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